Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said the National Medical Products Administration accepted drug registration applications for two drugs developed by two of its subsidiaries, a Monday bourse filing said.
The NMPA accepted the application of Polymyxin B sulfate for Injection of Guilin Pharmaceutical, while Shanghai Zhaohui Pharmaceutical had its application for Labetalol Hydrochloride Injection accepted by the regulator.
Polymyxin B sulfate for Injection is meant for the treatment of gram-negative bacterial infections while the Labetalol Hydrochloride Injection is for the treatment of severe hypertension.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。